ClinicaliQ Trial Snapshot
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors — Recruiting • Phase I • Oncology • NCT05836324.
- What is being tested: INCA33890, a novel investigational agent, is undergoing a dose-escalation safety and tolerability study in patients with advanced or metastatic solid tumors to establish the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE).
- Patient eligibility overview: The trial recruits patients with select advanced or metastatic solid tumors who have limited or exhausted standard treatment options, representing a population where novel therapeutic approaches are clinically needed.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Eligibility Snapshot
- : * ≥18 years old * Histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol. * Part 1: Participants must have experienced disease progression after treatment with, be intolerant to, or be ineligible for, or refused available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit. Part 2: depending on cohort, participants may have received or not prior treatment for the malignancy under study. * ECOG performance status score of 0 or 1. * Willingness to undergo pre- and on-treatment tumor biopsy (core or excisional). Biopsies are mandatory depending on the cohorts. * Presence of measurable disease according to RECIST v1.1.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.